MedTrace Logo

Perimenopausal Effects of Estradiol on Reward Responsiveness

NCT02255175 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2019-11-12

Study results available
· View outcomes & findings →

Summary

Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women either with or without depression.

Conditions

  • Perimenopausal Depression

Interventions

DRUG

Estradiol

Participants will receive transdermal estradiol (100μg/day) for 3 weeks

DRUG

Progesterone

Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Crystal Schiller, PhD · University of North Carolina at Chapel Hill Psychiatry Department

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
44 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2018-10-17
Completion
2018-10-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02255175 on ClinicalTrials.gov